Pheon Therapeutics, an antibody-drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, entered into an exclusive licence agreement with Biocytogen Pharmaceuticals Co. Ltd., a global biotech company focused on the discovery of novel antibody therapeutics. Under the terms of the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary RenMice platforms. Biocytogen will receive an upfront payment and is ...